Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Ramucirumab Plus Docetaxel (Doc) Vs Pbo Plus Doc For Stage Iv Nsclc After Disease Progression (Revel): Indian Sub-Group Analysis

K. Prabhash,D. Doval, B. Rangarajan,N. Somani,A. Pruthi, Y. D'Yachova, T. Puri

Journal of Thoracic Oncology（2021）

Cited 0|Views0
No score
Abstract
The REVEL study demonstrated improved survival of ramucirumab (RAM) plus docetaxel (DOC) as second-line therapy in patients with Stage IV Non-small cell lung cancer (NSCLC). We conducted an exploratory analysis of safety and efficacy in the Indian patient subgroup.
More
Translated text
Key words
ramucirumab, NSCLC, REVEL
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined